214 related articles for article (PubMed ID: 36920307)
41. LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.
Layer JH; Alford CE; McDonald WH; Davé UP
Mol Cell Biol; 2016 Feb; 36(3):488-506. PubMed ID: 26598604
[TBL] [Abstract][Full Text] [Related]
42. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
Hirose K; Inukai T; Kikuchi J; Furukawa Y; Ikawa T; Kawamoto H; Oram SH; Göttgens B; Kiyokawa N; Miyagawa Y; Okita H; Akahane K; Zhang X; Kuroda I; Honna H; Kagami K; Goi K; Kurosawa H; Look AT; Matsui H; Inaba T; Sugita K
Blood; 2010 Aug; 116(6):962-70. PubMed ID: 20519628
[TBL] [Abstract][Full Text] [Related]
43. The LMO2 oncogene regulates DNA replication in hematopoietic cells.
Sincennes MC; Humbert M; Grondin B; Lisi V; Veiga DF; Haman A; Cazaux C; Mashtalir N; Affar el B; Verreault A; Hoang T
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1393-8. PubMed ID: 26764384
[TBL] [Abstract][Full Text] [Related]
44. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.
Appert A; Nam CH; Lobato N; Priego E; Miguel RN; Blundell T; Drynan L; Sewell H; Tanaka T; Rabbitts T
Cancer Res; 2009 Jun; 69(11):4784-90. PubMed ID: 19487290
[TBL] [Abstract][Full Text] [Related]
45. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
[TBL] [Abstract][Full Text] [Related]
46. LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.
Lu L; Wang J; Fang F; Guo A; Jiang S; Tao Y; Zhang Y; Li Y; Zhang K; Zhang Z; Zhuo R; Chu X; Li X; Tian Y; Ma L; Sang X; Chen Y; Yu J; Yang Y; Cao H; Gao J; Lu J; Hu S; Pan J; He H
Cell Death Dis; 2023 Aug; 14(8):518. PubMed ID: 37573405
[TBL] [Abstract][Full Text] [Related]
47. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice.
O'Neil J; Billa M; Oikemus S; Kelliher M
Oncogene; 2001 Jun; 20(29):3897-905. PubMed ID: 11439353
[TBL] [Abstract][Full Text] [Related]
48. [Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism].
Nan Z; Liang Y; Fu R; Liu H; Ruan EB; Wang XM; Wang GJ; Qu W; Liu H; Wu YH; Song J; Xing LM; Guan J; Li LJ; Wang HQ; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):556-61. PubMed ID: 23815897
[TBL] [Abstract][Full Text] [Related]
49. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
50. Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model.
Pais H; Ruggero K; Zhang J; Al-Assar O; Bery N; Bhuller R; Weston V; Kearns PR; Mecucci C; Miller A; Rabbitts TH
Sci Rep; 2019 Apr; 9(1):5760. PubMed ID: 30962539
[TBL] [Abstract][Full Text] [Related]
51. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
52. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
53. FoxN1-dependent thymic epithelial cells promote T-cell leukemia development.
Ghezzo MN; Fernandes MT; Pacheco-Leyva I; Rodrigues PM; Machado RS; Araújo MAS; Kalathur RK; Futschik ME; Alves NL; Dos Santos NR
Carcinogenesis; 2018 Dec; 39(12):1463-1476. PubMed ID: 30256907
[TBL] [Abstract][Full Text] [Related]
54. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
[TBL] [Abstract][Full Text] [Related]
55. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
56. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
[TBL] [Abstract][Full Text] [Related]
57. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
[TBL] [Abstract][Full Text] [Related]
58. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract][Full Text] [Related]
59. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.
Liu Y; Wang Z; Huang D; Wu C; Li H; Zhang X; Meng B; Li Z; Zhu T; Yang S; Sun W
Oncotarget; 2017 Feb; 8(6):9513-9524. PubMed ID: 27880729
[TBL] [Abstract][Full Text] [Related]
60. Genetic and epigenetic determinants mediate proneness of oncogene breakpoint sites for involvement in TCR translocations.
Larmonie NS; van der Spek A; Bogers AJ; van Dongen JJ; Langerak AW
Genes Immun; 2014 Mar; 15(2):72-81. PubMed ID: 24304972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
